Atorvastatin vs Rosuvastatin: Which Statin Is Right for You?

The Quick Answer

Both atorvastatin and rosuvastatin are high-intensity statins that reduce LDL cholesterol by 50–63%. Rosuvastatin is slightly more potent per milligram and has fewer drug interactions. Atorvastatin has a longer track record and is often slightly cheaper. For most patients, either is an excellent choice — the decision often comes down to drug interactions, tolerability, and cost.

Side-by-Side Comparison

LDL-Lowering Potency

Rosuvastatin is the most potent statin available on a per-milligram basis. Rosuvastatin 10 mg reduces LDL by approximately the same amount as atorvastatin 20 mg. At maximum doses, rosuvastatin 40 mg achieves about 63% LDL reduction versus approximately 55% with atorvastatin 80 mg.

For patients who need very aggressive LDL lowering — such as those with familial hypercholesterolemia or very high cardiovascular risk — rosuvastatin may achieve target LDL with a lower dose, which can reduce side effect risk.

Drug Interactions: A Key Differentiator

Atorvastatin is primarily metabolized by the CYP3A4 enzyme. This means it interacts with a wide range of medications that inhibit or induce CYP3A4, including:

• Antibiotics: clarithromycin, erythromycin
• Antifungals: itraconazole, ketoconazole
• HIV medications: ritonavir, lopinavir, saquinavir
• Immunosuppressants: cyclosporine
• Grapefruit juice (large amounts)

Rosuvastatin has minimal CYP metabolism and is not significantly affected by CYP3A4 inhibitors. This makes it a better choice for patients on complex medication regimens — particularly those with HIV, transplant recipients on cyclosporine, or patients on multiple antibiotics.

Renal Impairment

Atorvastatin is primarily eliminated via bile (fecal excretion) and does not require dose adjustment in renal impairment. Rosuvastatin has significant renal excretion and accumulates in patients with severe kidney disease (eGFR <30 mL/min/1.73m²), where the maximum recommended dose is 10 mg/day. For patients with chronic kidney disease, atorvastatin is generally preferred.

Side Effects: Are They Different?

Both statins have similar side effect profiles. Muscle aches (myalgia) are the most common complaint with both drugs. Head-to-head comparison trials have not shown a significant difference in myopathy rates between atorvastatin and rosuvastatin at equivalent LDL-lowering doses.

Both statins carry the same class warnings for myopathy/rhabdomyolysis, new-onset diabetes, and liver enzyme elevations. Neither drug has been shown to be significantly safer than the other in terms of serious adverse events.

Clinical Trial Evidence

Atorvastatin has an extensive evidence base from landmark trials including ASCOT-LLA (primary prevention in hypertension), TNT (intensive vs. moderate dosing in stable CAD), CARDS (diabetes), and MIRACL (acute coronary syndrome). These trials collectively enrolled over 50,000 patients and established atorvastatin as a cornerstone of cardiovascular prevention.

Rosuvastatin's pivotal trial is JUPITER (2008), which enrolled 17,802 patients with elevated CRP but normal LDL and showed a 44% reduction in major cardiovascular events versus placebo. The SATURN trial (2011) directly compared atorvastatin 80 mg vs. rosuvastatin 40 mg in patients with CAD and found rosuvastatin produced greater regression of coronary atherosclerosis despite similar cardiovascular event rates.

Which Should You Choose?

There is no universally "better" statin — the right choice depends on individual factors:

Cost Comparison

Both statins are available as generics. Atorvastatin generics have been available since 2011 and are widely available for $4–$25/month. Rosuvastatin generics became available in 2016 and typically cost $10–$30/month. With a GoodRx or RxGo discount card, both can often be obtained for under $15/month at most pharmacies.

See our detailed atorvastatin cost guide and rosuvastatin cost guide for current pharmacy pricing.

References

1. Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359(21):2195-2207.
2. Nicholls SJ, et al. Effect of two intensive statin regimens on progression of coronary disease (SATURN). N Engl J Med. 2011;365(22):2078-2087.
3. LaRosa JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease (TNT). N Engl J Med. 2005;352(14):1425-1435.